Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| CVRx, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Carotid baroreflex activation therapy (BAT) by the Rheos® system produces a sustained fall in blood pressure in patients with resistant hypertension. Since the activation electrodes are implanted at the level of the carotid sinus, it is conceivable that the nearby located carotid body chemoreceptors are stimulated as well. Physiological stimulation of carotid chemoreceptors not only raises respiration, but it also increases sympathetic activity which may in part counteract the effects of BAT. The aim of the present study is to investigate whether there is evidence for concomitant carotid chemoreflex activation during BAT. We hypothesized that there is no clinically relevant co-activation of the carotid body chemoreceptors during BAT in patients with resistant hypertension.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Resistant hypertensive patients with Rheos system | We will program 6 electrical device activation setting twice in a random order to see what happens with the aforementioned respiratory and cardiovascular variables. The following electrical settings will be programmed for 4 minutes each setting:
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in arterial CO2 (PaCO2) during baroreflex activation therapy | During one hour several device activation settings will be programmed at random. During each device setting we will collect arterial blood samples to check for PaCO2. | 6 times during different electrical activation settings within one hour |
| Measure | Description | Time Frame |
|---|---|---|
| Change in end-tidal CO2 during baroreflex activation therapy | Change in respiratory variables will be analyzed during the aforementioned time frame in which we will program several device activation settings. | 1 - 1.25 hour |
| Change in blood pressure during baroreflex activation therapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Subjects implanted with a BAT system will be invited to participate in this study. These are patients who were enrolled in the DEBuT-HET and Rheos Pivotal Trial and have given their permission to be approached for follow-up studies. Subjects are all >21 years of age and were all known with a blood pressure ≥160/90 mmHg despite optimal antihypertensive therapy before receiving BAT. It is essential to have the Rheos® device implanted to enable participation in this study, as we want to investigate the effect of electrical carotid sinus activation on the carotid body chemoreflex.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Teba Alnima, MD | Contact | 003143 3875367 | teba.alnima@mumc.nl |
| Name | Affiliation | Role |
|---|---|---|
| Abraham Kroon, MD, PhD | Maastricht University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maastricht University Medical Center+ | Recruiting | Maastricht | 6229 HX | Netherlands |
Not provided
| Label | URL |
|---|---|
| Overall description of the device and related safety and efficacy results | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C563514 | Hypertension Resistant to Conventional Therapy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Arterial blood for analysis of PaCO2, PaO2 and pH
The change in cardiovascular variables will be analyzed during each device activation setting |
| 1 - 1.25 hour |
| Change in respiratory rate during baroreflex activation therapy | Change in respiratory variables will be analyzed during the aforementioned time frame in which we will program several device activation settings. | 1 - 1.25 hour |
| Change in expiration time during baroreflex activation therapy | Change in respiratory variables will be analyzed during the aforementioned time frame in which we will program several device activation settings. | 1 - 1.25 hour |
| Change in heart rate during baroreflex activation therapy | The change in cardiovascular variables will be analyzed during each device activation setting | 1 - 1.25 hour |
| Change in peripheral vascular resistance during baroreflex activation therapy | The change in cardiovascular variables will be analyzed during each device activation setting | 1 - 1.25 hour |
| Change in forced expiratory volume-1 second (FEV1) before and after turning off the device | 2 hours |